# BioAdaptives Inc. (BDPT) · Edgar & Edgarette company card

> BioAdaptives (BDPT) grew revenue 44.3% in FY2025 to $0 million, operating margin -5702% against a -3.8% median for pharmaceutical preparations, equity -943% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1575142 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BDPT) · [JSON](https://www.pops4.com/boards/company/BDPT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $18,278 |
| Revenue growth, 1 year | 44.3% |
| Revenue growth per year | -2.0% |
| Operating margin | -5701.8% (prior year -4752.5%) |
| Net margin | -8523.4% |
| Operating cash flow | −$516,025 |
| Capital spending | $18,000 |
| Free cash flow | −$534,025 |
| Cash | $215,205 |
| Long-term debt | — |
| Total assets | $225,901 |
| Total equity | −$2M |
| Equity ÷ assets | -942.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -248.93 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$516K in FY2025); operating loss: a margin of -5701.8% in FY2025; revenue is hard to predict: its 80% range is ±70%

## Edgarette's reading

Exposure: revenue $18K (FY2025). Experience: revenue up 44.3% on the year, down 2.0% a year over 4 years; operating margin -5701.8%, down from -4752.5%. Soundness: equity -942.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $9K and $53K next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $8K to $60K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -5701.8% against a -3.8% median; growth 44.3% against 13.7%.

Range logged 2026-11-05, receipt 2e152505b00a23a5, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426000599/0001640334-26-000599-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426001379/0001640334-26-001379-index.htm))

## Recent filings

- 8-K · filed 2026-11-04 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426001712/0001640334-26-001712-index.htm)
- 10-Q · filed 2026-08-19 · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426001393/0001640334-26-001393-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426000911/0001640334-26-000911-index.htm)
- 10-K · filed 2026-04-14 · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/0001640334-26-000718-index.htm)
- 10-Q · filed 2025-11-14 · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033425002081/0001640334-25-002081-index.htm)
- 10-Q · filed 2025-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1575142/000164033425001493/0001640334-25-001493-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001575142.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1575142

## Cite

POPS4, Edgar & Edgarette: BioAdaptives Inc. (BDPT) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/BDPT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.